Evaluation of Modified PEG-anilinoquinazoline Derivatives As Potential Agents for EGFR Imaging in Cancer by Small Animal PET

Overview

Journal Mol Imaging Biol

Publisher Springer

Specialties Molecular Biology
Radiology

Date 2010 Apr 10

PMID 20379787

Citations 10

Authors

Maria A Pantaleo

Eyal Mishani

Cristina Nanni

Lorena Landuzzi

Stefano Boschi

Giordano Nicoletti

Samar Dissoki

Paola Paterini

Pier Poalo Piccaluga

Filippo Lodi

Pier-Luigi Lollini

Stefano Fanti

Guido Biasco

Affiliations

Soon will be listed here.

Abstract

Purpose: The in vivo evaluation of three modified polyethylene glycol (PEG)-anilinoquinazoline derivatives labeled with (124)I, (18)F, and (11)C as potential positron emission tomography (PET) bioprobes for visualizing epidermal growth factor receptor (EGFR) in cancer using small animal PET.

Procedures: Xenograft mice with the human glioblastoma cell lines U138MG (lacking EGFR expression) and U87MG.wtEGFR (transfected with an overexpressing human wild-type EGFR gene) were used. Static and dynamic PET imaging was conducted for all three PEGylated compounds. Tumor necrosis, microvessel density, and EGFR levels were evaluated by histopathology and enzyme-linked immunosorbent assay.

Results: Nineteen animal models were generated (two U138MG, three U87MG, 14 with both U138MG and U87MG bilateral masses). In static images, a slight increase in tracer uptake was observed in tumors, but in general, there was no retention of tracer uptake over time and no difference in uptake between U138MG and U87MG masses. In addition, no significant uptake was demonstrated in dynamic scans of the (18)F-PEG tracer. No necrosis was present except in four animals. MVD was 9.6 and 48 microvessels/×400 field in the U138GM and U87GM masses, respectively (p = 0.00008). Similarly, the microvessel grades were generally higher in the U87GM group (p = 0.002). Total EGFR amount was higher in U87MG than U138MG masses (p = 0.001), but the ratio of activated (pY1068) to total EGFR did not differ (p = 0.95).

Conclusions: PEGylated tracers labeled with (11)C, (124)I, and (18)F showed no significant difference in uptake between U138MG and U87MG glioblastoma xenograft mice. The tracer binding with EGFR could be influenced by activation of the tyrosine kinase portion of the receptor which was similar in U138MG and U87MG. Despite these results, these tracers should be investigated in animal models with mutant EGFR genes to determine whether aberrant receptor function plays a role in tumor uptake.

Citing Articles

The Development of Positron Emission Tomography Tracers for In Vivo Targeting the Kinase Domain of the Epidermal Growth Factor Receptor.

Hognasbacka A, Poot A, Vugts D, van Dongen G, Windhorst A Pharmaceuticals (Basel). 2022; 15(4).

PMID: 35455447 PMC: 9033078. DOI: 10.3390/ph15040450.

Drug delivery, biodistribution and anti-EGFR activity: theragnostic nanoparticles for simultaneous delivery of tyrosine kinase inhibitors and kinase activity biosensors.

Bofinger R, Weitsman G, Evans R, Glaser M, Sander K, Allan H Nanoscale. 2021; 13(44):18520-18535.

PMID: 34730152 PMC: 8601123. DOI: 10.1039/d1nr02770k.

Novel Receptor Tyrosine Kinase Pathway Inhibitors for Targeted Radionuclide Therapy of Glioblastoma.

Bolcaen J, Nair S, Driver C, Boshomane T, Ebenhan T, Vandevoorde C Pharmaceuticals (Basel). 2021; 14(7).

PMID: 34209513 PMC: 8308832. DOI: 10.3390/ph14070626.

Real-time molecular optical micro-imaging of EGFR mutations using a fluorescent erlotinib based tracer.

Patout M, Guisier F, Brune X, Bohn P, Romieu A, Sarafan-Vasseur N BMC Pulm Med. 2019; 19(1):3.

PMID: 30612556 PMC: 6322267. DOI: 10.1186/s12890-018-0760-z.

Recent Advances in the Development and Application of Radiolabeled Kinase Inhibitors for PET Imaging.

Bernard-Gauthier V, Bailey J, Berke S, Schirrmacher R Molecules. 2015; 20(12):22000-27.

PMID: 26690113 PMC: 6332294. DOI: 10.3390/molecules201219816.

References

Wang H, Yu J, Yang G, Song X, Sun X, Zhao S . Assessment of 11C-labeled-4-N-(3-bromoanilino)-6,7-dimethoxyquinazoline as a positron emission tomography agent to monitor epidermal growth factor receptor expression. Cancer Sci. 2007; 98(9):1413-6. PMC: 11160051. DOI: 10.1111/j.1349-7006.2007.00562.x. View

Ben-David I, Rozen Y, Ortu G, Mishani E . Radiosynthesis of ML03, a novel positron emission tomography biomarker for targeting epidermal growth factor receptor via the labeling synthon: [11C]acryloyl chloride. Appl Radiat Isot. 2003; 58(2):209-17. DOI: 10.1016/s0969-8043(02)00301-9. View

Dei Tos A . The biology of epidermal growth factor receptor and its value as a prognostic/predictive factor. Int J Biol Markers. 2007; 22(1 Suppl 4):S3-9. View

Baselga J . The EGFR as a target for anticancer therapy--focus on cetuximab. Eur J Cancer. 2001; 37 Suppl 4:S16-22. DOI: 10.1016/s0959-8049(01)00233-7. View

Shaul M, Abourbeh G, Jacobson O, Rozen Y, Laky D, Levitzki A . Novel iodine-124 labeled EGFR inhibitors as potential PET agents for molecular imaging in cancer. Bioorg Med Chem. 2004; 12(13):3421-9. DOI: 10.1016/j.bmc.2004.04.044. View

Memon A, Jakobsen S, Dagnaes-Hansen F, Sorensen B, Keiding S, Nexo E . Positron emission tomography (PET) imaging with [11C]-labeled erlotinib: a micro-PET study on mice with lung tumor xenografts. Cancer Res. 2009; 69(3):873-8. DOI: 10.1158/0008-5472.CAN-08-3118. View

Sharma S, Bell D, Settleman J, Haber D . Epidermal growth factor receptor mutations in lung cancer. Nat Rev Cancer. 2007; 7(3):169-81. DOI: 10.1038/nrc2088. View

Allegra C, Jessup J, Somerfield M, Hamilton S, Hammond E, Hayes D . American Society of Clinical Oncology provisional clinical opinion: testing for KRAS gene mutations in patients with metastatic colorectal carcinoma to predict response to anti-epidermal growth factor receptor monoclonal antibody therapy. J Clin Oncol. 2009; 27(12):2091-6. DOI: 10.1200/JCO.2009.21.9170. View

Salomon D, Brandt R, Ciardiello F, Normanno N . Epidermal growth factor-related peptides and their receptors in human malignancies. Crit Rev Oncol Hematol. 1995; 19(3):183-232. DOI: 10.1016/1040-8428(94)00144-i. View

10.

Pal A, Glekas A, Doubrovin M, Balatoni J, Namavari M, Beresten T . Molecular imaging of EGFR kinase activity in tumors with 124I-labeled small molecular tracer and positron emission tomography. Mol Imaging Biol. 2006; 8(5):262-77. DOI: 10.1007/s11307-006-0049-0. View

11.

Wang M, Gao M, Mock B, Miller K, Sledge G, Hutchins G . Synthesis of carbon-11 labeled fluorinated 2-arylbenzothiazoles as novel potential PET cancer imaging agents. Bioorg Med Chem. 2006; 14(24):8599-607. DOI: 10.1016/j.bmc.2006.08.026. View

12.

Pantaleo M, Nannini M, Fanti S, Boschi S, Lollini P, Biasco G . Molecular imaging of EGFR: it's time to go beyond receptor expression. J Nucl Med. 2009; 50(7):1195-6. DOI: 10.2967/jnumed.109.063909. View

13.

Lynch T, Bell D, Sordella R, Gurubhagavatula S, Okimoto R, Brannigan B . Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med. 2004; 350(21):2129-39. DOI: 10.1056/NEJMoa040938. View

14.

Piccaluga P, Visani G, Pileri S, Ascani S, Grafone T, Isidori A . Clinical efficacy and antiangiogenic activity of thalidomide in myelofibrosis with myeloid metaplasia. A pilot study. Leukemia. 2002; 16(9):1609-14. DOI: 10.1038/sj.leu.2402596. View

15.

Pantaleo M, Fanti S, Nannini M, Boschi S, Nanni C, Maleddu A . What oncologists need and require from nuclear medicine. Eur J Nucl Med Mol Imaging. 2008; 35(10):1761-5. DOI: 10.1007/s00259-008-0825-y. View

16.

Liu N, Li M, Li X, Meng X, Yang G, Zhao S . PET-based biodistribution and radiation dosimetry of epidermal growth factor receptor-selective tracer 11C-PD153035 in humans. J Nucl Med. 2009; 50(2):303-8. DOI: 10.2967/jnumed.108.056556. View

17.

Weidner N, Semple J, Welch W, Folkman J . Tumor angiogenesis and metastasis--correlation in invasive breast carcinoma. N Engl J Med. 1991; 324(1):1-8. DOI: 10.1056/NEJM199101033240101. View

18.

Dissoki S, Aviv Y, Laky D, Abourbeh G, Levitzki A, Mishani E . The effect of the [18F]-PEG group on tracer qualification of [4-(phenylamino)-quinazoline-6-YL]-amide moiety--an EGFR putative irreversible inhibitor. Appl Radiat Isot. 2007; 65(10):1140-51. DOI: 10.1016/j.apradiso.2007.04.014. View

19.

Nicholson R, Gee J, Harper M . EGFR and cancer prognosis. Eur J Cancer. 2001; 37 Suppl 4:S9-15. DOI: 10.1016/s0959-8049(01)00231-3. View

20.

Cai W, Niu G, Chen X . Multimodality imaging of the HER-kinase axis in cancer. Eur J Nucl Med Mol Imaging. 2007; 35(1):186-208. DOI: 10.1007/s00259-007-0560-9. View